Seizure detection using coordinate data

Abstract
A seizure detection device includes a coordinate data interface configured to receive coordinate data for a human, a memory to store coordinate data for a defined location of the human, and a seizure detector configured to identify a seizure event responsive to the coordinate data.
Description
FIELD OF THE INVENTION

The present disclosure generally relates to systems and methods for detecting, predicting or logging seizures in a human patient and, optionally, providing a therapy in response thereto. More particularly, the present disclosure relates to a system and methods for detecting physiological changes indicative of a seizure in a patient having an implanted seizure control device, and using coordinate data, such as GPS, to improve seizure detection algorithm specificity.


DESCRIPTION OF THE RELATED ART

Implantable devices have been developed for delivering targeted nervous stimulation at preprogrammed intervals as a therapy for neurological disorders, such as epileptic seizures. It has been shown that measurable parameters of cardiac activity correlate with epileptic seizure events. Consequently, methods have been developed for recognizing a seizure event by measuring changes in heart rate. One challenge to this methodology is that many reasons exist that can cause a heart rate change, such as physical exertion. Thus, heart rate changes alone can give a misleading indication of a seizure event if the heart rate changes are precipitated by other causes. The present disclosure is directed to overcoming, or at least reducing the effects, of one or more of the issues set forth above.


SUMMARY OF THE INVENTION

It has been recognized that it would be desirable to discriminate heart rate changes associated with a seizure from heart rate changes precipitated by other causes, when determining whether to trigger nervous stimulation for seizure control.


It has also been recognized that information regarding activity or location or position of an individual can help distinguish heart rate changes that accompany a seizure from those that relate to other causes.


In accordance with one aspect thereof, the present disclosure provides a seizure detection device, including a coordinate data interface configured to receive coordinate data for a human, a memory to store coordinate data for a defined location where the human has previously been, and a seizure detector configured to identify a seizure event responsive to the coordinate data.


In accordance with another aspect thereof, the present disclosure provides a system for nerve stimulation, including a pulse generator device suitable for subcutaneous implantation into a human body, and a coordinate data interface configured to receive coordinate data for the human body. A memory is also provided to store coordinate data for a defined location where the human has previously been, and an activation device is configured to activate the pulse generation device responsive to the coordinate data.


In accordance with yet another aspect thereof, the disclosure provides a method for detecting seizures, including the steps of receiving coordinate data for a human body, determining a seizure threshold responsive to the coordinate data, and identifying a seizure event responsive to the seizure threshold.


These and other embodiments of the present application will be discussed more fully in the description. The features, functions, and advantages can be achieved independently in various embodiments of the claimed invention, or may be combined in yet other embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic representation of a human subject implanted with an embodiment of a subcutaneous vagus nerve stimulation system, including apparatus for receiving coordinate data of the human subject and identifying a seizure event responsive to the coordinate data.



FIG. 2 is a schematic representation of a human subject implanted with another embodiment of a subcutaneous vagus nerve stimulation system, including apparatus for identifying a seizure episode based upon coordinate data associated with a human subject.



FIG. 3 is a schematic representation of another embodiment of a system for identifying a seizure episode based upon coordinate data associated with a human subject.



FIG. 4 is a schematic representation of another embodiment of a system for identifying a seizure episode based upon coordinate data associated with a human subject, where the coordinate data can be obtained from devices other than a GPS system.



FIG. 5 is a block diagram outlining the steps in an embodiment of a method for determining a seizure threshold and identifying a seizure episode responsive to coordinate data.





While the disclosure is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. However, it should be understood that the disclosure is not intended to be limited to the particular forms disclosed. Rather, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope as defined by the appended claims.


DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

Illustrative embodiments are described below as they might be employed in a system for seizure detection using coordinate data. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.


Further aspects and advantages of the various embodiments will become apparent from consideration of the following description and drawings. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that modifications to the various disclosed embodiments may be made, and other embodiments may be utilized, without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense.


As used herein, the term “implantable” means a device that can be completely implanted into a human or animal body, with no portions of the apparatus extending outside the body after implantation.


As used herein, the terms “implantable device” and “implantable medical device” or “IMD” mean any type of electrical device that is implantable into a human or animal body, and is configured to monitor or affect a function of the body. Examples of implantable medical devices include cardiac pacemakers, nerve stimulation devices, and implantable drug delivery devices.


There are a variety of implantable devices that can be used for monitoring and affecting physiological or biological function of a human body. Such devices include cardiac pacemakers, implantable drug delivery systems and nerve stimulation devices. Among the latter are implantable devices for nerve stimulation, such as vagus nerve stimulation (VNS). VNS was approved by the FDA in 1998 as an adjunctive therapy for epilepsy with partial onset seizures. VNS is achieved through an implanted pulse generator that delivers a bipolar, biphasic pulse to the vagus nerve. The implant procedure is very similar to the implantation of a pacemaker. The generator is implanted subcutaneously, typically in the upper left pectoral region. An electric lead is connected between the pulse generator and one or more electrodes that are attached to the vagus nerve.


Shown in FIG. 1 is a schematic diagram of one embodiment of an implantable vagus nerve stimulation system, indicated generally at 10, implanted into a patient 12. The system includes a pulse generator 14, and a tether or lead 16 that has one or more electrodes 18 at its distal end. The tether and electrodes are collectively referred to as the lead, and the lead provides an interface between the pulse generator 14 and the electrodes 18. The electrodes 18 are attachable to the vagus nerve 20. An implantable VNS system of this type and having these basic features is known to those of skill in the art, and is commercially available, such as from Cyberonics, Inc. of Houston, Tex.


The implantable VNS system 10 can also include an antenna 24, a GPS receiver 26, and a microprocessor 28 with digital memory 30. These elements can be included within the housing of the pulse generation device 14. It will be appreciated by those of skill in the art that the pulse generation device can also include other elements that are not shown in FIG. 1, such as a rechargeable battery, etc. for providing electrical power to the device through periodic inductive recharging of the battery. The antenna 24 is a common element for an implantable pulse generation device, and is often provided to send and/or receive data and programming and control instructions from an external communications device, such as a heart monitor patch 44. This allows the implanted device to receive programming and control instructions from the external communications device, and to transmit data regarding operation of the pulse generation device. Communications and control with implanted devices is well known and widely used. Devices such as pacemakers and the like are routinely programmed and/or controlled via wireless communication methods, such as the Medical Information Communication System protocol (MICS), which uses radio waves to transmit information to and from implanted devices.


The pulse generator 14 can be a multi-programmable device, which allows a physician to set various parameters of operation of the device. The programmable parameters can include signal amplitude (e.g., 0-3.5 mA), frequency (e.g., 1-30 Hz), pulse width (e.g., 130-1000 μs), signal ON time (e.g., 7-60 sec) and signal OFF time (e.g., 0.2-180 min). It is to be appreciated that these pulse parameters are only exemplary, and that other parameters can also be used. The pulses can be delivered at the specified amplitude and frequency over the course of the ON time, and then during the OFF time, no stimulation takes place. This type of device typically does not stimulate continuously because it has been found that the antiepileptic effect tends to last much longer than the actual time of stimulation. In one embodiment, pulse settings can be 2 mA, at 15 Hz frequency, 250 μs pulse width, with a 30 sec ON time, and 5 min OFF time. The variability in parameters allows the physician to adjust for greater efficacy or less severe side effects, depending on the patient.


The implantable nerve stimulation device can also include programming and structure to allow adjustment of its operation in real-time based upon detected physiological conditions of the patient in whom it is implanted. Of particular interest in this disclosure, a seizure detector can be provided in conjunction with an implanted device, such as the pulse generation device 14, to identify a seizure event based upon at least one body parameter and coordinate data indicating position or motion of the patient. In one embodiment, the pulse generation device 14 can include a device for detecting the cardiac cycle, as one example of a body parameter or physiological condition of the human subject. There are many different ways to detect cardiac cycles, and several of these are shown in FIG. 1. For example, the implanted pulse generation device 14 can include multiple electrodes 32 on its outer surface or casing (but electrically insulated from the casing), the electrodes being in contact with bodily fluids and thereby detecting a change in electrical potential, which gives an ECG (Electro-CardioGram) signal indicative of the patient's cardiac cycle. As another alternative, another lead 34 can extend from the pulse generation device 14 to a separate implanted heart monitoring device 36, which includes a group of spaced electrodes (not shown) that measure ECG. Such an implanted device can be anchored to a rib or other anatomical structure. As another alternative, a lead with electrodes attached directly to the heart (not shown) can also be used.


As another alternative for monitoring the cardiac cycle of the subject 12, a pressure transducer 38 can be placed next to an artery, such as the carotid artery 40. It is to be appreciated that in the case of vagus nerve stimulation, the carotid artery 40 is relatively close to the vagus nerve 20 in the neck region. Thus, a surgeon could extend a branch 42 of the lead 16 toward the carotid artery during implantation of the nerve stimulation electrodes 18, and implant the pressure transducer 38. This pressure transducer detects changes in pressure adjacent to the artery, which are indicative of the cardiac cycle of the subject.


While the heart monitoring devices discussed above involve implanted structure, it is also to be appreciated that external devices can also be used for monitoring the subject's heart. For example, another method for detecting cardiac cycles can include the use of an external patch 44 which can be adhered to the skin of the chest of the subject 12 and can be similar to current Holter monitors. The patch can include a group of spaced electrodes (not shown), which detect the subject's ECG, in the same manner as implanted electrodes. The use of external adhesive electrodes for measuring the cardiac cycle is widely known in the medical arts. The patch 44 can include internal circuitry and a power source (not shown) and an antenna 46, so that the cardiac cycle information can be wirelessly transmitted to the pulse generation device 14. It is to be understood that, while the patch 44 is shown having an external antenna 46, this is for illustrative purposes only, and does not necessarily represent actual physical structure. It will be appreciated that the antenna can be an internal part of the patch device itself. This sort of patch can be a disposable device, which the subject can wear for a period of time and then replace with a new one whenever desired. The external patch is thus one example of an external communication device that can collect and/or receive seizure event data and threshold parameters associated with physical coordinates of the patient (e.g., GPS data).


It is to be appreciated that other heart monitoring devices, whether implanted or external, can be used in a seizure detection system as disclosed herein. For example, the discussion of the external patch 44 above applies equally to Holter monitors, which come in many varieties and sizes (e.g., simple strap versions commonly used during exercise or a larger “pager style” connected to multiple adhesive electrode patches). Whatever method is used for detecting the subject's cardiac cycle, data regarding the heart rate, heart rate variability, etc. of the subject are continuously transmitted back to the microprocessor 28 of the pulse generator 14. This allows the pulse generation device to be programmed to adjust nerve stimulation based upon the events detected from the cardiac cycle of the subject.


It is known that measurable parameters of cardiac activity correlate with epileptic seizure events. For example, an accelerated heart rate (tachycardia) often accompanies the onset of a seizure event. As used herein, the term “tachycardia” is used in a broader sense than that customarily used by cardiologists—it is used to generally refer to any increase in heart rate. When tachycardia is detected by the microprocessor 28, its programming can cause the pulse generation device to initiate nervous stimulation to treat the seizure. The microprocessor can include activation circuitry that is programmed and configured to activate the implantable device in response to at least one of the coordinate data and the body parameter or body signal data. In this way, the microprocessor 28 of the pulse generation device operates as an activation device for initiating nervous stimulation via the pulse generator. It is believed that nervous stimulation upon detection of a possible seizure can shorten the duration or lessen the severity of a seizure event. Moreover, it is believed that timely nervous stimulation upon first detection of seizure precursor symptoms can even prevent a seizure from fully developing. It is to be understood that to say that the seizure detector merely detects tachycardia can be a simplification. The algorithm for analyzing the cardiac cycle can do more than merely detect an elevated heart rate. Specifically, the algorithm may use matching techniques to identify tachycardia typical of seizures, use accelerometer or other data to confirm or deny seizure detections, or use linear or non-linear properties of heart rate variability (and it's derivatives) to detect or categorize seizure events.


One challenge to this methodology is that there are many possible causes for heart rate and cardiac cycle changes, such as physical exertion. The inventor has recognized that it is desirable to discriminate between the causes of cardiac cycle change when determining whether a seizure event has begun, and whether to trigger nerve stimulation for seizure control. The inventor has determined that information regarding an individual's activity or location can help distinguish cardiac cycle changes or other detectable physiological parameters that accompany a seizure from those that relate to other causes. Advantageously, the inventor has developed systems and methods disclosed herein for obtaining and using coordinate data related to the location of the human subject for more accurately identifying seizure events, and for determining a seizure threshold responsive to the coordinate data. In particular, in various embodiments, the apparatus and methods disclosed herein involve the use of GPS (Global Positioning System satellite data) or other coordinate measurement systems for seizure detection and logging specificity improvement.


GPS transceivers have become a common part of many electrical devices. For example, laptop computers, personal digital assistants (PDA's) and many or most smart phones now incorporate a GPS transceiver. The implanted vagus nerve stimulation system shown in FIG. 1 also includes a GPS transceiver 26, which is interconnected to the antenna 24 and the microprocessor 28 and memory 30. The GPS transceiver is one type of coordinate data interface, and is configured to receive coordinate data for the human patient. With these elements, the microprocessor can periodically or continuously determine the subject's location using the publically-accessible GPS satellite system. The coordinate data can then be stored in the memory 30. This data can represent a defined location for the patient. This can be a user-defined location or a previously designated location, for example. The location can also be a mobile location. It is to be appreciated that the defined location is not limited to locations where the patient has been. For example, it can be advantageous to be able to program in, for example, a beach, hunting camp or other area where the patient has not been but intends to go, and where a seizure would present elevated risks of injury to self or others. As is well known, the GPS system allows tracking of latitude, longitude and altitude of the transceiver at any given time, based upon the position of the transceiver 26 relative to multiple GPS satellites 48, and also provides very accurate time data. Moreover, receiving data regarding changes in position over time allows the system (e.g., the microprocessor 28) to also determine velocity and direction of motion of the subject at any time. In other words, the microprocessor can be programmed as a movement calculator, which can determine movement in response to coordinate data over time.


While the GPS transceiver 26 is shown incorporated into the implanted pulse generation device in FIG. 1, the GPS transceiver can be placed in other locations associated with the patient's body, such as an external communications device. An external communications device can thus provide the coordinate data interface discussed above, and can function as an activation device for the implanted device. The external communications device can include activation circuitry and programming for activating the implantable device (e.g. via wireless signals) in response to the coordinate data and the body parameter or body signal data. A variety of types of external devices can be used. Some of these are shown in FIG. 2. For example, a GPS transceiver 50 can be incorporated into a smart phone 52 or similar device that is substantially constantly kept in the possession of the person. Alternatively, a wristwatch or wristwatch-like device 54 or other wearable device can include a GPS transceiver which receives locational information and transmits this information wirelessly to the pulse generation device 14. Other wearable or external communication devices can also be used. The smart phone 52 and wristwatch device 54 are shown in FIG. 2 with antennas, which are intended to represent the wireless communications capability of the devices, rather than the shape or position of an actual antenna structure. The antenna allows the external device to receive GPS signals from the satellites 48, and transmit the received GPS data to the pulse generation device 14 using Bluetooth or some other wireless transmission protocol, for example. The wireless external device can be a cellular device, and can house the coordinate data interface and the activation device for the pulse generator. In this way coordinate signals from a wireless external communication device can be transmitted to the pulse generation device. It is recognized that the accuracy of seizure detection can be affected if the GPS device is not kept upon the person of the epileptic patient.


Having the GPS transceiver included within a device other than the pulse generation device 14 can be desirable for power conservation. It will be apparent that power consumption of a GPS transceiver that is in substantially constant communication with the GPS satellite system and a microprocessor that analyzes the positional information can use significant power, which is at a premium with implanted devices. Thus, having an external GPS device can reduce the power demands of the implanted device. Since the external device and the implanted device are presumably kept in relatively close proximity (both upon the person of the epileptic patient), wireless transmission between these devices can be at a much lower power than communication with the GPS system or some other wireless system, thus reducing the power demands upon the implanted device.


Additionally, microprocessing tasks and analysis can be transferred to an external device, rather than being performed by the microprocessor 28 of the pulse generation device, with the results of those microprocessing tasks transmitted to the implanted device. This can also conserve power for the implanted device. For example, the microprocessor associated with a smart phone 52 or wristwatch device 54 or some other external device can be programmed to receive cardiac cycle information (e.g, from an external heart monitoring device or transmitted from the pulse generator 14 or some other implanted device) as well as locational information (GPS, etc.), and perform the analysis discussed herein to distinguish seizure related tachycardia from other causes. The external device can then transmit operational commands or other information to the pulse generation device 14 that can affect its operation, when a seizure event is detected.


Having a GPS transceiver on or associated with the subject 12, along with an implanted or external seizure detector, such as a heart monitoring device, as shown in FIG. 1, allows the system to use location and motion information in conjunction with seizure detection (e.g. heart rate) information to increase confidence in a seizure detection determination. For example, if a heart rate increase accompanies a change in velocity to a fairly constant 3-7 mph, then the system can reduce seizure declaration likelihood (i.e., increase an adaptive threshold), because the change in velocity indicates that the change in heart rate likely results from the person walking or jogging. On the other hand, if no contemporary change in velocity is detected in association with the other seizure detection sensors, then the system can increase the seizure detection likelihood (i.e. reduce the adaptive threshold), so that this heart rate event is considered more likely to accompany a seizure event. This is the basic analytical method for detecting seizures using coordinate data. In this way the seizure detection system is programmed with a threshold evaluator or threshold determining element (i.e. threshold determining logic), which can determine a dynamic seizure detection threshold in response to the coordinate data (representing location and/or motion). Threshold parameters associated with various physical locations or coordinates can be stored in the memory of the seizure detection device (e.g. the implanted device or external communications device).


A flowchart outlining the basic steps in this method is provided in FIG. 5. The system first receives the coordinate data (step 500), which can be GPS data or some other data. Coordinate data also includes data regarding motion, which can involve time-based analysis of GPS or other positional information in order to determine velocity. In either case, the positional or velocity-related data is referred to herein as coordinate data. Based upon this data, the system analyzes or modifies a seizure detection threshold (step 502) with reference to the patient's location or motion. As shown by return arrow 504, so long as no signal indicating a possible seizure is received by the associated heart monitoring device (step 506), the system simply returns to step 500 and continues to monitor and receive the coordinate data, and periodically adjust the seizure detection threshold as needed (step 502).


However, if a signal indicating a possible seizure (e.g., tachycardia or other signal) is received (at step 506), the system then determines whether a seizure is probably occurring (step 508). This analysis is based upon the modified seizure detection threshold that is part of a seizure detection algorithm, which was determined at step 502, as represented by dashed arrow 510. The difference between analytical steps 506 and 508 is the difference between possible and probable. Step 506 merely determines that a seizure is possible, based upon the received signal. At step 508, it is determined whether a seizure is probable or not, based upon the modified seizure detection threshold. As noted above, once the system has determined, from the coordinate data, how to adjust the seizure detection threshold, its ability to selectively identify a probable seizure is improved. If, in view of the modified seizure detection threshold, it is determined that the detected signal indicating a possible seizure is not likely to be indicative of a seizure, the system can again return to step 500 and continue to monitor and receive the coordinate data, and periodically adjust the seizure detection threshold (step 502). However, if a seizure is detected in view of the modified seizure detection threshold, one or more of various actions can be initiated, as indicated in boxes 512, 514 and 516. These are discussed in more detail below.


The configuration described above allows the system to be used in a variety of ways, some of which are illustrated in FIG. 3. Shown in FIG. 3 is a patient 300 having an implanted VNS device 302, and a smart phone 304 and wristwatch device 306. These external devices are intended to be indicative of any external GPS and/or microprocessor device. It is to be understood that the operational capabilities illustrated in FIG. 3 can be applied whether the implanted device is associated with a coordinate data system like that of FIG. 1 or FIG. 2, or other embodiments. The depiction of the patient 300 is intended to represent the person in any common condition—such as standing, walking, running, etc. Whether through the implanted device 302 or an external device 304, 306 (depending on which device includes a GPS transceiver), the person's position is continually monitored via the GPS satellite system 308, as indicated by dashed line 310. By tracking the person's position over time, the microprocessor that receives the GPS information (like the GPS transceiver, the microprocessor can be part of the implanted pulse generation device 302 or part of an external device 304, 306) can determine the velocity of the person in three dimensions at any time.


Similarly, the microprocessor can incorporate automotive travel logic into the seizure detection algorithm to account for instances when the defined location of the person is mobile. Shown in FIG. 3 is a person 312 in an automobile 314. Though not shown, this person also has a GPS based seizure detection system, like the person 300, and this system is in communication with the satellite based GPS system, as indicated at 316. The microprocessor associated with the seizure detection system can be programmed so that patterns of velocity indicative of automotive travel are recognized and used to modify the seizure detection threshold. Patterns of velocity indicative of automotive travel can include motion at anything above a running speed (e.g., 20 mph), for example. When automotive travel is recognized, the system can adjust (either increase or decrease) the seizure declaration likelihood. On one hand, the system can reduce the adaptive threshold in the circumstance of probable automotive travel because (1) there is less risk of harm from a seizure when traveling as a passenger in a motor vehicle, and (2) there is less likelihood of exertional tachycardia while traveling in a car or bus.


The seizure detection threshold can also vary depending upon the person's relationship to the vehicle—i.e. whether a driver or passenger. For example, tachycardia can be considered more likely for a driver 312, especially in crowded or difficult traffic conditions, than for a passenger 318, as shown in FIG. 3. This sort of factor can come into play in other situations, too. Thus, the seizure detection system disclosed herein can include another feature shown in FIG. 5. In addition to receiving coordinate data (step 500) and modifying the seizure detection threshold based on that information (step 502), the system can also prompt a patient to input relevant locational or conditional information (step 501). For example, when the system detects velocity data indicative of automotive travel, the patient's smart phone or other external device (52 in FIG. 2) can prompt the user with a question such as “Are you traveling in a motor vehicle?” The patient can then enter the appropriate answer to confirm their condition. The system can then ask a follow-up question such as “Are you driving or are you a passenger?”


In this way the coordinate data interface prompts the user to provide information that can identify their location, thus allowing any location to become a user-defined or designated location. In one embodiment, the coordinate data interface can display a predetermined list of location types, from which the user can select to identify the location. For example, the display may list “home”, “work”, “shopping” and “vehicle” as possible location choices. Multiple nested lists can be involved. When the user selects one, the system can then store the coordinate data of that location in conjunction with the identifier. In another embodiment, the coordinate data interface can be configured to receive an identifying name for the defined location via input of the user or a caretaker or medical personnel, for example. The named location can also have a location type associated with it, such as via a predetermined list of location types, in the manner discussed above.


The system can also prompt for risk factor inputs. These risk factor inputs can then be associated with physical coordinates of a defined location, and can be used to determine the seizure threshold responsive to the risk factor inputs and the coordinate data. The seizure detection algorithm's thresholds can be lowered to be more sensitive to possible seizures when the user is in a risky location. The risk of harm to the user increases in locations such as the gym, swimming pool, bath tub, driver's seat of a vehicle, kitchen, staircase, on a bicycle, and so forth. Each location can have a corresponding risk factor associated with it or the user can input the risk factor necessary for a certain location. The risk factor input can simply be the coordinate data and modify the risk factor dynamically as the user, for example, moves through the house from the bed, to the bath tub, to the kitchen, to the dining room, and then to the vehicle. The user can also input the risk factor by defining a location (e.g., a bicycle) as the user arrives at the location. The user can also input a risk factor without defining the location by, for example, setting a high risk factor when rock climbing and then input a low risk factor when the user eats a picnic lunch near the rock he climbed.


After the user has been prompted to enter relevant information, the system can then adjust the seizure detection threshold. In one embodiment, if a person is a passenger, the seizure detection algorithm can operate normally, but if the person is a driver, the algorithm can become more aggressive (e.g., lowering a threshold) to act upon every possible seizure, for example. Alternatively, the system can use the knowledge that the patient is the driver to separate out tachycardia induced by the stress of driving from tachycardia (or other cardiac cycle events) resulting from seizures.


While much of the above discussion has considered seizure detection based upon sensing tachycardia and cardiac cycles, it is to be understood that this is only one example of a body parameter or physiological condition that can be indicative of a possible seizure event. It is to be appreciated that seizure detection can be accomplished using any one or more of a wide variety of body parameters, in addition to cardiac cycles. For example, seizure detection data can be obtained from cardiovascular signals, respiratory signals, skin signals, pupillary signals, temperature signals, peristaltic signals, brain signals, cranial nerve signals, spinal cord signals, peripheral nerve signals, autonomic nerve or ganglia signals, biomedical presence or concentration signals (i.e. detection of a particular chemical species), body kinetic, position and force signals, and others. Additionally or alternatively, neurological signals, such as those generated by the brain or cranial nerves can be used for detecting a seizure. Exemplary body parameter sensor(s) can include electrocardiography (EKG) devices, accelerometers, inclinometers, pupillometers, face or body temperature monitors, skin resistance monitors, and/or sound and pressure sensors, among others. Those of skill in the art will be aware that sensor(s) to detect these and other body parameters are commercially available, and can be placed in, on, or near a particular organ, tissue, nerve, or blood vessel of the patient, or outside the patient's body, such as on the patient's skin or in the patient's environment.


Referring back to FIG. 3, the system can be configured with additional functionality. As shown by dashed lines 320 and 322, the seizure detection system can incorporate mobile communications technology that allows wireless communication with a cellular phone system (represented by a cell tower 324), which can further connect into the publicly switched telephone system (PSTN) 326. This allows the seizure detection system to communicate with a base station, medical professional, hospital or the like, as represented by building 328, when a seizure is detected. Such remote communications can be desirable for many possible reasons, such as for health monitoring, emergency medical assistance, transmitting seizure related data, providing notifications or programming updates for an implanted device, etc. Various options for action upon detection of a seizure are indicated in FIG. 5, and these can include options that involve remote communications. For example, as indicated in box 512, upon detection of a seizure the system can actuate an implanted nerve stimulation device (14 in FIG. 1) to initiate nervous stimulation. In certain circumstances and certain locations the system can dial 911 to request emergency medical aid. Other actions related to the patient can also be taken.


Additionally, upon detection of a seizure the seizure detection system can begin recording data of the patient and other conditions, perhaps at a faster rate than normally. For example, if the system normally checks position and motion at a rate of once every 4 seconds when no seizure is detected, detection of a seizure could initiate electronic recording of the person's location, movement, heart rate, blood pressure, and other possible factors at a much higher refresh rate—e.g. every 1 second—during the seizure event. This information can be recorded or logged by the microprocessor (step 514) and/or transmitted to a remote location (step 516) if desired. A remote monitoring location or facility can also include its own wireless communication capability, as indicated by antenna 330, to allow direct communications with seizure detection systems, as opposed to or in addition to communications through the PSTN 326.


It is also to be appreciated that the seizure detection system can be used when there is no implanted nerve stimulation device. That is, for purposes of studying seizures, it may be desirable to provide a patient with heart monitoring devices, as discussed above, and an external device of some kind to detect and transmit data regarding seizures, even in the absence of any mechanism for treating them. This approach can be suitable for some patients and desirable from a research standpoint to gather seizure information.


The system can also be configured for other functions and for operation in other conditions, as shown in FIG. 4. The seizure detection system disclosed herein can incorporate stair-climbing logic to help prevent false seizure indications from exertion that results from stair climbing. For example, shown in FIG. 4 is a person 400 climbing a flight of stairs 402 in a building 404. In a situation like this, the seizure detection system can detect a pattern of velocity and altitude change that is indicative of stair-climbing. Since this sort of action is likely to raise one's heart rate, the adaptive seizure detection threshold can be reduced in a manner specific to stair-climbing. That is, since stair climbing presents a more extreme case of exertion, it is therefore more likely to induce an accelerated heart rate that is not associated with a seizure event.


The system can also incorporate neural network self-programming, so that the adaptive thresholds “learn” to match a particular patient's pattern of how speed and altitude changes result in heart rate changes. Over time, the adaptive threshold can be “trained” to follow an expected pattern of exertion versus resulting heart rate (or other autonomic) change. A seizure detection declaration is made to be more likely when the pattern of cardiac cycle deviates from the cardiac cycle that would have normally been expected given contemporary velocity data.


In addition to adjusting an adaptive heart rate threshold in conjunction with data regarding velocity or motion of the individual, the system can also use GPS positional or coordinate data to modify the seizure detection threshold based on specific coordinate locations. That is, the system can use a logical neural network self-programming and learning for recognizing specific positional patterns. For example, using data from a GPS satellite system 406, the system can logically determine that the patient is in a position of a bed 408 (e.g. on an upper floor 410 of a known residential building 404, in a substantially constant position for several continuous hours each day). If a ‘bed’ locational determination is made, adaptive thresholds can be adjusted to attempt to discriminate from patterns of normal sleep behaviors. Where the system determines this type of location, sudden tachycardia can be indicative either of a seizure event, or of waking and rising. To distinguish between sudden heart rate change due to a seizure and sudden heart rate change upon getting out of bed, the system can be programmed to recognize that a heart rate jump upon arising from bed is likely to occur after a change in body position. Consequently, GPS or other signals that detect body or positional changes can screen this out.


Similarly, logical determination that the patient is in a position of a car's normal patterned parking space (i.e., within a garage 412 of a residence 404) can trigger corresponding logical conclusions. If a ‘car’ locational determination is made, adaptive thresholds can be adjusted to ‘automotive travel’ mode immediately, rather than having to wait for a pattern of velocity that indicates automotive travel.


Relevant data can also be obtained from devices in addition to a GPS transceiver. For example, as shown in FIG. 2, the pulse generation device can also include an accelerometer 60 that is interconnected to the microprocessor 28. There are a wide variety of low cost, miniature accelerometers that are commercially available, and can be incorporated into an implantable device, or an external device, such a smart phone 52, wristwatch 54, etc. For example, many cardiac pacemakers currently include accelerometers to detect exercise, and can adjust pacing accordingly. Such an accelerometer device can accurately detect acceleration along three axes (up-down, forward-back, left-right), allowing the microprocessor 28 to detect the onset of motion of the patient in any direction. An inclinometer (not shown) can similarly be used to give an indication of the patient's posture, such as lying down, reclining, standing, etc. A neural network logical self-programming pattern recognition algorithm can be incorporated into the programming of the microprocessor to correlate patterns of data from the accelerometer, inclinometer, etc. with data from the GPS receiver.


As noted above, receiving GPS signals generally requires a line of sight to GPS satellites. However, there are many locations, such as inside a building, etc., where it may be difficult or impossible to obtain a GPS signal. Such a situation is suggested in FIG. 4. Correlating the accelerometer data with the most recently obtained GPS data allows adaptive threshold adjustment in the absence of a GPS signal. The accelerometer data can represent an ‘activity level’ in a way that is derived from the GPS data that indicates ‘activity level’ based on velocity changes. Thus, after a learning period of sufficient simultaneous GPS and accelerometry recording, the pattern recognition learning algorithm can have the ability to adjust seizure declaration thresholds in the absence of a GPS signal, which may be the case for many indoor locations.


Additionally, other position-finding technologies can also be used to determine location when a GPS signal is limited, such as at certain indoor locations. Other position-finding technologies that can be used can include local positioning systems, RFID systems, toll tag technologies, cell phone positional methodologies, internal radio positional networks, proximity sensors, motion sensors, and acoustic broadcasts and sensors (especially those tuned to inaudible frequencies) which can determine the location and/or motion of a patient in many locations. These types of systems can provide a local coordinate system that can provide local coordinate data regarding the position or motion of the patient. One of these types of systems is suggested in FIG. 4. It is possible that GPS detection can work within a building, as indicated by the communication line between the satellite 406 and the person 400. However, the home 404 may prevent the reception of GPS signals in many instances. Consequently, this building is equipped with a plurality of detection devices 414a-d, which can allow local detection of the position and motion of a patient inside the building.


These detection devices 414 can be sensors which actually sense position and/or motion (e.g. motion detectors), or they can be broadcast devices that broadcast a signal (e.g. a radio signal), and then sense reflected information. For example, the detection devices 414 can provide signals (e.g. proximity signals) to an IMD or external device upon the person of the patient, and the IMD or external device can then interpret the proximity data to independently determine the position and motion of the patient to detect the patient 400 climbing a flight of stairs 402, for example, even if the GPS system is not able to detect it. Similarly, the detection devices can detect when the person is sitting relatively still, as at 416, or in or near the bed 408. The detection devices 414 for this type of application can be cell phone positional sensors, an internal radio positional network, proximity sensors, motion sensors, or others. Thus, for example, viewing FIG. 4, detection device 414a can be a radio-frequency transmitter, detection device 414b can be a motion sensor, detection device 414c can be a proximity sensor, and detection device 414d can be an acoustic broadcast sensor.


In an interior or other location where a GPS signal may not be available, the user can ‘set up’ the home or commonly visited place with detection devices of two or more types. One type of detection device can be used to indicate that the area is associated with a ‘high risk’. Another type of detection device can be associated with a ‘low risk’ location. In instances when there is only one type of detection device present, the default programming can consider decision making without the condition of ‘high risk’ or ‘low risk’ biasing the decision.


In the case of a tachycardia-based detection algorithm, one example of a high risk location can be the person's the bed 208, since tachycardia when in one's bed should be rare except in the event of an actual seizure. As another example, a bathtub (not shown) can be considered a high risk location because, even though non-seizure tachycardia could happen in the bathtub, the consequences of an unattended seizure in the bathtub carry high risk. In high risk locations the propensity to declare an event and respond can be biased toward more vigilance. On the other hand, an example of a low risk location could be a stairway 402. It is highly probable that tachycardia will be associated with exertion in a stairway. Consequently, the threshold for seizure responsive action in a stairway can be relaxed, since a tachycardia event experienced at the stairway is more likely to be due to exertion, rather than a seizure event.


The locational data that is collected when setting up the commonly visited locations can also be presented for use in patient care. For example, medical professionals, caregivers, and/or patients can analyze the patient's sleeping habits, daily rituals, frequency of exposure to ‘high risk’ locations, the amount of time spent in particular locations of interest, and general activity levels. These types of factors can be referred to as lifestyle factors, and can be evaluated and considered in the seizure detection system disclosed herein. For example, this data can help determine the patient's quality of life or, among other things, behavioral patterns that may lead to changes in the prescribed therapy. The conglomerated and trended positional and body sensor data may be used to collaterally quantify and communicate lifestyle factors such as in the form of standard indices like Physical Activity Level (PAL)/Physical Activity Index (PAI), Total Energy Expenditure (TEE), and other existing standards used to quantify state of health. Such indices and their trends may themselves be used to adjust a seizure detection declaration threshold, reveal trends that may be predictive of seizure propensity, or simply for presenting a measure of health improvement or decline to the healthcare provider.


An additional feature of the seizure detection system shown in FIG. 4 is a bedside monitoring unit or base station 420. This unit can operate in much the same way as other external devices disclosed above (such as the smart phone 52 in FIG. 2). It can transmit and receive low power signals with an implanted nerve stimulation device, and can receive or be programmed with GPS or other positional data. Advantageously, the bedside unit 420 can be hard-wired into a communications system, such as the PSTN, represented by wires 422, allowing rapid and reliable communications with a remote monitoring station 424 or other remote location. The base station can also include wireless capability, allowing it to communicate directly with a wireless telephone system, represented by cell tower 426, or other wireless devices. The base station and other external devices allow some device other than an implanted device to do the “heavy lifting” of communications and analysis for seizure detection, so that power demands on the implanted device are minimized.


Alternatively, in an embodiment, similar to FIG. 2, the seizure detection algorithm can be processed in either the IMD or the external device. The computational ‘heavy lifting’ can be performed on the external device whenever it is within range and operational, but when the external device is unavailable, the IMD can be programmed to perform the computational chores, even at the expense of battery use, so as not to lose functionality of the system as a whole.


It is to be appreciated that the system and method disclosed herein can also apply to cardiac pacemakers. That is, a pacemaker is an implantable device that can be provided with a coordinate data interface in the manner disclosed herein, and include programming to determine or adjust operational parameters based upon coordinate and/or motion data and a detected physiological condition, such as cardiac cycles.


The system and method disclosed herein can thus improve the accuracy of automated seizure detection devices and algorithms. This system has the greatest potential to improve specificity of automated seizure declarations. It can reduce battery consumption by an implanted nerve stimulation device by avoiding false alarms and incorrectly identified needs for therapy delivery. It can also reduce anxiety and disruption by avoiding false alarms for alerting-type systems. Additionally, this system and method can improve the tracking of disease progression by making seizure counts more accurate.


Although various embodiments have been shown and described, the invention is not so limited and will be understood to include all such modifications and variations as would be apparent to one skilled in the art. For example, equivalent elements may be substituted for those specifically shown and described, certain features may be used independently of other features, and the number and configuration of various vehicle components described above may be altered, all without departing from the spirit or scope of the invention as defined in the appended claims.


Such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed exemplary embodiments. It is to be understood that the phraseology of terminology employed herein is for the purpose of description and not of limitation. Accordingly, the foregoing description of the exemplary embodiments of the invention, as set forth above, are intended to be illustrative, not limiting. Various changes, modifications, and/or adaptations may be made without departing from the spirit and scope of this invention.

Claims
  • 1. A seizure detection device comprising: a coordinate data interface configured to receive coordinate data indicating a coordinate location of a patient;a memory configured to store the coordinate data associated with a defined location; anda seizure detector configured to detect a seizure event in the patient based on the coordinate data and body parameter data corresponding to at least one body parameter.
  • 2. The seizure detection device of claim 1, wherein the coordinate data includes global positioning system data obtained from a global positioning system, local coordinate data obtained from a local coordinate system, or both.
  • 3. The seizure detection device of claim 2, wherein the coordinate data includes time data, and wherein the global positioning system data, the local coordinate data, or both, includes velocity data, acceleration data, or both.
  • 4. The seizure detection device of claim 1, further comprising a motion detector configured to detect motion of the patient, wherein the seizure detector is responsive to the coordinate data and the motion of the patient.
  • 5. The seizure detection device of claim 4, wherein the motion detector comprises an accelerometer.
  • 6. The seizure detection device of claim 1, wherein the seizure detector is further configured to: dynamically determine a seizure detection threshold based at least in part on the coordinate data; andcompare the body parameter data to the seizure detection threshold.
  • 7. The seizure detection device of claim 1, further comprising a communication interface configured to communicate with an external communication device: the body parameter data, seizure event data, seizure detection threshold data, the coordinate data, or a combination thereof.
  • 8. The seizure detection device of claim 1, wherein the coordinate data includes altitude data.
  • 9. The seizure detection device of claim 1, further comprising a movement calculator configured to determine an amount of movement of the patient responsive to the coordinate data.
  • 10. The seizure detection device of claim 1, wherein the body parameter data is determined based on a cardiovascular signal, a respiratory signal, a skin signal, a pupillary signal, a temperature signal, a peristaltic signal, a brain signal, a cranial nerve signal, a spinal cord signal, a peripheral nerve signal, an autonomic nerve signal, an autonomic ganglia signal, a biomedical presence signal, a biomedical concentration signal, a body kinetic signal, a body position signal, a body force signal, or a combination of two or more thereof.
  • 11. The seizure detection device of claim 7, wherein the external communication device activates an implantable medical device based at least in part on the body parameter data, the coordinate data, or both.
  • 12. The seizure detection device of claim 11, wherein the implantable medical device includes a pulse generation device for nerve stimulation to the patient.
  • 13. A method comprising: receiving coordinate data indicating a coordinate location of a patient;determining a seizure threshold based at least in part on the coordinate data; anddetecting a seizure event in the patient based at least in part on the seizure threshold.
  • 14. The method of claim 13, wherein receiving the coordinate data includes receiving global positioning system data from a global positioning system, receiving local coordinate system data from a local coordinate system, or both.
  • 15. The method of claim 14, wherein receiving the coordinate data includes receiving time data, and wherein receiving the global positioning system data, the local coordinate system data, or both, includes receiving velocity data, acceleration data, or both.
  • 16. The method of claim 13, further comprising determining an amount of movement of the patient based on the coordinate data, wherein the seizure event is detected in the patient based on the coordinate data and the amount of movement of the patient.
  • 17. The method of claim 13, further comprising logging seizure event data associated with the coordinate data.
  • 18. The method of claim 13, further comprising sending seizure event data associated with the coordinate data to an external communication device.
  • 19. The method of claim 13, further comprising receiving input data indicating an activity being performed by the patient, wherein the seizure threshold is determined based on the input data.
  • 20. The method of claim 19, wherein the input data further indicates a location where the activity is being performed.
US Referenced Citations (563)
Number Name Date Kind
4172459 Hepp Oct 1979 A
4197856 Northrop Apr 1980 A
4291699 Geddes et al. Sep 1981 A
4320766 Alihanka et al. Mar 1982 A
4541432 Molina-Negro et al. Sep 1985 A
4573481 Bullara Mar 1986 A
4702254 Zabara Oct 1987 A
4867164 Zabara Sep 1989 A
4920979 Bullara May 1990 A
4949721 Toriu et al. Aug 1990 A
4979511 Terry, Jr. Dec 1990 A
5025807 Zabara Jun 1991 A
5062169 Kennedy et al. Nov 1991 A
5113869 Nappholz et al. May 1992 A
5137020 Wayne et al. Aug 1992 A
5154172 Terry, Jr. et al. Oct 1992 A
5179950 Stanislaw Jan 1993 A
5186170 Varrichio et al. Feb 1993 A
5188104 Wernicke et al. Feb 1993 A
5194847 Taylor et al. Mar 1993 A
5203326 Collins Apr 1993 A
5205285 Baker, Jr. Apr 1993 A
5213568 Lattin et al. May 1993 A
5215086 Terry, Jr. et al. Jun 1993 A
5215089 Baker, Jr. Jun 1993 A
5222494 Baker, Jr. Jun 1993 A
5231988 Wernicke et al. Aug 1993 A
5235980 Varrichio et al. Aug 1993 A
5237991 Baker, Jr. et al. Aug 1993 A
5243980 Mehra Sep 1993 A
5251634 Weinberg Oct 1993 A
5263480 Wernicke et al. Nov 1993 A
5269302 Swartz et al. Dec 1993 A
5269303 Wernicke et al. Dec 1993 A
5299569 Wernicke et al. Apr 1994 A
5304206 Baker, Jr. et al. Apr 1994 A
5311876 Olsen et al. May 1994 A
5313953 Yomtov et al. May 1994 A
5330507 Schwartz Jul 1994 A
5330515 Rutecki et al. Jul 1994 A
5334221 Bardy Aug 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5404877 Nolan et al. Apr 1995 A
5425373 Causey, III Jun 1995 A
5513649 Gevins et al. May 1996 A
5522862 Testerman et al. Jun 1996 A
5523742 Simkins et al. Jun 1996 A
5540730 Terry, Jr. et al. Jul 1996 A
5540734 Zabara Jul 1996 A
5571150 Wernicke et al. Nov 1996 A
5610590 Johnson et al. Mar 1997 A
5611350 John Mar 1997 A
5645077 Foxlin Jul 1997 A
5645570 Corbucci Jul 1997 A
5651378 Matheny et al. Jul 1997 A
5658318 Stroetmann et al. Aug 1997 A
5683422 Rise et al. Nov 1997 A
5690681 Geddes et al. Nov 1997 A
5690688 Noren et al. Nov 1997 A
5700282 Zabara Dec 1997 A
5707400 Terry, Jr. et al. Jan 1998 A
5716377 Rise et al. Feb 1998 A
5720771 Snell Feb 1998 A
5743860 Hively et al. Apr 1998 A
5748113 Torch May 1998 A
5792186 Rise Aug 1998 A
5800474 Benabid et al. Sep 1998 A
5807284 Foxlin Sep 1998 A
5808552 Wiley et al. Sep 1998 A
5833709 Rise et al. Nov 1998 A
5853005 Scanlon et al. Dec 1998 A
5879309 Johnson et al. Mar 1999 A
5905436 Dwight et al. May 1999 A
5913876 Taylor et al. Jun 1999 A
5916181 Socci et al. Jun 1999 A
5916239 Geddes et al. Jun 1999 A
5928272 Adkins et al. Jul 1999 A
5941906 Barreras, Sr. et al. Aug 1999 A
5942979 Luppino Aug 1999 A
5978702 Ward et al. Nov 1999 A
5978972 Stewart et al. Nov 1999 A
5987352 Klein et al. Nov 1999 A
5995868 Osorio et al. Nov 1999 A
6016449 Fischell et al. Jan 2000 A
6018682 Rise Jan 2000 A
6048324 Socci et al. Apr 2000 A
6061593 Fischell et al. May 2000 A
6073048 Kieval et al. Jun 2000 A
6083249 Familoni Jul 2000 A
6091992 Bourgeois et al. Jul 2000 A
6095991 Krausman et al. Aug 2000 A
6104956 Naritoku et al. Aug 2000 A
6115628 Stadler et al. Sep 2000 A
6115630 Stadler et al. Sep 2000 A
6128538 Fischell et al. Oct 2000 A
6134474 Fischell et al. Oct 2000 A
6162191 Foxlin Dec 2000 A
6163281 Torch Dec 2000 A
6167311 Rezai Dec 2000 A
6171239 Humphrey Jan 2001 B1
6175764 Loeb et al. Jan 2001 B1
6205359 Boveja Mar 2001 B1
6208894 Schulman et al. Mar 2001 B1
6208902 Boveja Mar 2001 B1
6221908 Kilgard et al. Apr 2001 B1
6246344 Torch Jun 2001 B1
6248080 Miesel et al. Jun 2001 B1
6253109 Gielen Jun 2001 B1
6269270 Boveja Jul 2001 B1
6272379 Fischell et al. Aug 2001 B1
6304775 Iasemidis et al. Oct 2001 B1
6315740 Singh Nov 2001 B1
6324421 Stadler et al. Nov 2001 B1
6337997 Rise Jan 2002 B1
6339725 Naritoku et al. Jan 2002 B1
6341236 Osorio et al. Jan 2002 B1
6356784 Lozano et al. Mar 2002 B1
6356788 Boveja Mar 2002 B2
6361507 Foxlin Mar 2002 B1
6361508 Johnson et al. Mar 2002 B1
6366813 DiLorenzo Apr 2002 B1
6366814 Boveja Apr 2002 B1
6374140 Rise Apr 2002 B1
6397100 Stadler et al. May 2002 B2
6427086 Fischell et al. Jul 2002 B1
6429217 Puskas Aug 2002 B1
6441731 Hess Aug 2002 B1
6449512 Boveja Sep 2002 B1
6459936 Fischell et al. Oct 2002 B2
6463328 John Oct 2002 B1
6466822 Pless Oct 2002 B1
6473639 Fischell et al. Oct 2002 B1
6473644 Terry, Jr. et al. Oct 2002 B1
6477418 Plicchi et al. Nov 2002 B2
6480743 Kirkpatrick et al. Nov 2002 B1
6484132 Hively et al. Nov 2002 B1
6501983 Natarajan et al. Dec 2002 B1
6505074 Boveja et al. Jan 2003 B2
6532388 Hill et al. Mar 2003 B1
6539263 Schiff et al. Mar 2003 B1
6542081 Torch Apr 2003 B2
6542774 Hill et al. Apr 2003 B2
6549804 Osorio et al. Apr 2003 B1
6556868 Naritoku et al. Apr 2003 B2
6560486 Osorio et al. May 2003 B1
6564102 Boveja May 2003 B1
6587719 Barrett et al. Jul 2003 B1
6587727 Osorio et al. Jul 2003 B2
6594524 Esteller et al. Jul 2003 B2
6599250 Webb et al. Jul 2003 B2
6609025 Barrett et al. Aug 2003 B2
6610713 Tracey Aug 2003 B2
6611715 Boveja Aug 2003 B1
6611783 Kelly, Jr. et al. Aug 2003 B2
6615081 Boveja Sep 2003 B1
6615085 Boveja Sep 2003 B1
6622038 Barrett et al. Sep 2003 B2
6622041 Terry, Jr. et al. Sep 2003 B2
6622047 Barrett et al. Sep 2003 B2
6628985 Sweeney et al. Sep 2003 B2
6628987 Hill et al. Sep 2003 B1
6629990 Putz et al. Oct 2003 B2
6647296 Fischell et al. Nov 2003 B2
6656125 Misczynski et al. Dec 2003 B2
6656960 Puskas Dec 2003 B2
6668191 Boveja Dec 2003 B1
6671555 Gielen et al. Dec 2003 B2
6671556 Osorio et al. Dec 2003 B2
6684105 Cohen et al. Jan 2004 B2
6721603 Zabara et al. Apr 2004 B2
6730047 Socci et al. May 2004 B2
6735474 Loeb et al. May 2004 B1
6738671 Christophersom et al. May 2004 B2
6760626 Boveja Jul 2004 B1
6763256 Kimball et al. Jul 2004 B2
6768969 Nikitin et al. Jul 2004 B1
6786877 Foxlin Sep 2004 B2
6788975 Whitehurst et al. Sep 2004 B1
6793670 Osorio et al. Sep 2004 B2
6819953 Yonce et al. Nov 2004 B2
6819956 DiLorenzo Nov 2004 B2
6832114 Whitehurst et al. Dec 2004 B1
6836685 Fitz Dec 2004 B1
6850601 Jones et al. Feb 2005 B2
6879850 Kimball Apr 2005 B2
6882881 Lesser et al. Apr 2005 B1
6885888 Rezai Apr 2005 B2
6904390 Nikitin et al. Jun 2005 B2
6920357 Osorio et al. Jul 2005 B2
6923784 Stein Aug 2005 B2
6931274 Williams et al. Aug 2005 B2
6934580 Osorio et al. Aug 2005 B1
6934585 Schloss Aug 2005 B1
6944501 Pless Sep 2005 B1
6957107 Rogers Oct 2005 B2
6961618 Osorio et al. Nov 2005 B2
6984993 Ariav Jan 2006 B2
6985771 Fischell et al. Jan 2006 B2
6990377 Gliner et al. Jan 2006 B2
7006859 Osorio et al. Feb 2006 B1
7006872 Gielen et al. Feb 2006 B2
7010351 Firlik et al. Mar 2006 B2
7024247 Gliner et al. Apr 2006 B2
7035684 Lee Apr 2006 B2
7054792 Frei et al. May 2006 B2
7058453 Nelson et al. Jun 2006 B2
7068842 Liang et al. Jun 2006 B2
7076288 Skinner Jul 2006 B2
7077810 Lange et al. Jul 2006 B2
7079977 Osorio et al. Jul 2006 B2
7104947 Riehl et al. Sep 2006 B2
7110820 Tcheng et al. Sep 2006 B2
7112319 Broderick et al. Sep 2006 B2
7127370 Kelly et al. Oct 2006 B2
7134996 Bardy Nov 2006 B2
7139677 Hively et al. Nov 2006 B2
7146211 Frei et al. Dec 2006 B2
7146217 Firlik et al. Dec 2006 B2
7146218 Esteller et al. Dec 2006 B2
7149572 Frei et al. Dec 2006 B2
7164941 Misczynski et al. Jan 2007 B2
7167743 Heruth et al. Jan 2007 B2
7167750 Knudson et al. Jan 2007 B2
7174206 Frei et al. Feb 2007 B2
7177678 Osorio et al. Feb 2007 B1
7188053 Nikitin et al. Mar 2007 B2
RE39539 Torch Apr 2007 E
7204833 Osorio et al. Apr 2007 B1
7209786 Brockway Apr 2007 B2
7209787 DiLorenzo Apr 2007 B2
7221981 Gliner May 2007 B2
7228167 Kara Jun 2007 B2
7231254 DiLorenzo Jun 2007 B2
7236830 Gliner Jun 2007 B2
7236831 Firlik et al. Jun 2007 B2
7242983 Frei et al. Jul 2007 B2
7242984 DiLorenzo Jul 2007 B2
7254439 Misczynski et al. Aug 2007 B2
7263467 Sackellares et al. Aug 2007 B2
7274298 Frank Sep 2007 B2
7277758 DiLorenzo Oct 2007 B2
7280867 Frei et al. Oct 2007 B2
7282030 Frei et al. Oct 2007 B2
7289844 Misczynski et al. Oct 2007 B2
7292890 Whitehurst et al. Nov 2007 B2
7295881 Cohen et al. Nov 2007 B2
7299096 Balzer et al. Nov 2007 B2
7302298 Lowry et al. Nov 2007 B2
7304580 Sullivan et al. Dec 2007 B2
7305268 Gliner et al. Dec 2007 B2
7313440 Miesel Dec 2007 B2
7314451 Halperin et al. Jan 2008 B2
7321837 Osorio et al. Jan 2008 B2
7324850 Persen et al. Jan 2008 B2
7324851 DiLorenzo Jan 2008 B1
7330760 Heruth et al. Feb 2008 B2
7346391 Osorio et al. Mar 2008 B1
7353063 Simms, Jr. Apr 2008 B2
7353064 Gliner et al. Apr 2008 B2
7373199 Sackellares et al. May 2008 B2
7385443 Denison Jun 2008 B1
7389144 Osorio et al. Jun 2008 B1
7389147 Wahlstrand et al. Jun 2008 B2
7395113 Heruth et al. Jul 2008 B2
7401008 Frei et al. Jul 2008 B2
7403820 DiLorenzo Jul 2008 B2
7420472 Tran Sep 2008 B2
7433732 Carney et al. Oct 2008 B1
7447545 Heruth et al. Nov 2008 B2
7454245 Armstrong et al. Nov 2008 B2
7488293 Marcovecchio et al. Feb 2009 B2
7488294 Torch Feb 2009 B2
7491181 Heruth et al. Feb 2009 B2
7494464 Rzesnitzek et al. Feb 2009 B2
7502643 Farringdon et al. Mar 2009 B2
7515054 Torch Apr 2009 B2
7539532 Tran May 2009 B2
7539533 Tran May 2009 B2
7539543 Schiff et al. May 2009 B2
7558622 Tran Jul 2009 B2
7565132 Ben Jul 2009 B2
7590453 Heruth et al. Sep 2009 B2
7612680 Eubank et al. Nov 2009 B2
7620456 Gliner et al. Nov 2009 B2
7629890 Sullivan et al. Dec 2009 B2
7643655 Liang et al. Jan 2010 B2
7647121 Wahlstrand et al. Jan 2010 B2
7658112 Nakamura Feb 2010 B2
7666151 Sullivan et al. Feb 2010 B2
7714757 Denison et al. May 2010 B2
7717848 Heruth et al. May 2010 B2
RE41376 Torch Jun 2010 E
7733224 Tran Jun 2010 B2
7747318 John et al. Jun 2010 B2
7769464 Gerber et al. Aug 2010 B2
7775993 Heruth et al. Aug 2010 B2
7792583 Miesel et al. Sep 2010 B2
7801603 Westlund et al. Sep 2010 B2
7801618 Pless Sep 2010 B2
7801743 Graves et al. Sep 2010 B2
7813802 Tcheng et al. Oct 2010 B2
7822481 Gerber et al. Oct 2010 B2
7827011 Devaul et al. Nov 2010 B2
7831305 Gliner Nov 2010 B2
7847628 Denison Dec 2010 B2
7866212 Ariav et al. Jan 2011 B2
7899545 John Mar 2011 B2
7935076 Estes et al. May 2011 B2
RE42471 Torch Jun 2011 E
7957809 Bourget et al. Jun 2011 B2
7965833 Meir et al. Jun 2011 B2
7974671 Fujiwara et al. Jul 2011 B2
7996076 Burns et al. Aug 2011 B2
7999857 Bunn et al. Aug 2011 B2
8000789 Denison et al. Aug 2011 B2
8000794 Lozano Aug 2011 B2
8021299 Miesel et al. Sep 2011 B2
8027730 John et al. Sep 2011 B2
8027737 Kokones et al. Sep 2011 B2
8075499 Nathan et al. Dec 2011 B2
8109891 Kramer et al. Feb 2012 B2
20010032059 Kelly et al. Oct 2001 A1
20020072782 Osorio et al. Jun 2002 A1
20020099417 Naritoku et al. Jul 2002 A1
20020116030 Rezai Aug 2002 A1
20020151939 Rezai Oct 2002 A1
20020188214 Misczynski et al. Dec 2002 A1
20030040680 Hassert et al. Feb 2003 A1
20030074032 Gliner Apr 2003 A1
20030083716 Nicolelis et al. May 2003 A1
20030083726 Zeijlemaker et al. May 2003 A1
20030125786 Gliner et al. Jul 2003 A1
20030130706 Sheffield et al. Jul 2003 A1
20030144829 Geatz et al. Jul 2003 A1
20030181954 Rezai Sep 2003 A1
20030181958 Dobak Sep 2003 A1
20030195588 Upton et al. Oct 2003 A1
20030208212 Cigaina Nov 2003 A1
20030210147 Humbard Nov 2003 A1
20030212440 Boveja Nov 2003 A1
20030236474 Singh Dec 2003 A1
20030236558 Whitehurst et al. Dec 2003 A1
20040006278 Webb et al. Jan 2004 A1
20040030365 Rubin et al. Feb 2004 A1
20040088024 Firlik et al. May 2004 A1
20040111045 Sullivan et al. Jun 2004 A1
20040122484 Hatlestad et al. Jun 2004 A1
20040122485 Stahmann et al. Jun 2004 A1
20040133119 Osorio et al. Jul 2004 A1
20040138516 Osorio et al. Jul 2004 A1
20040138517 Osorio et al. Jul 2004 A1
20040138647 Osorio et al. Jul 2004 A1
20040138711 Osorio et al. Jul 2004 A1
20040153129 Pless et al. Aug 2004 A1
20040158119 Osorio et al. Aug 2004 A1
20040158165 Yonce et al. Aug 2004 A1
20040172085 Knudson et al. Sep 2004 A1
20040172091 Rezai Sep 2004 A1
20040172094 Cohen et al. Sep 2004 A1
20040176812 Knudson et al. Sep 2004 A1
20040176831 Gliner et al. Sep 2004 A1
20040199212 Fischell et al. Oct 2004 A1
20040225335 Whitehurst et al. Nov 2004 A1
20040249302 Donoghue et al. Dec 2004 A1
20040249416 Yun et al. Dec 2004 A1
20050004621 Boveja et al. Jan 2005 A1
20050020887 Goldberg Jan 2005 A1
20050021092 Yun et al. Jan 2005 A1
20050021103 DiLorenzo Jan 2005 A1
20050021104 DiLorenzo Jan 2005 A1
20050021105 Firlik et al. Jan 2005 A1
20050021106 Firlik et al. Jan 2005 A1
20050021107 Firlik et al. Jan 2005 A1
20050021118 Genau et al. Jan 2005 A1
20050022606 Partin et al. Feb 2005 A1
20050027284 Lozano et al. Feb 2005 A1
20050033378 Sheffield et al. Feb 2005 A1
20050033379 Lozano et al. Feb 2005 A1
20050038484 Knudson et al. Feb 2005 A1
20050049515 Misczynski et al. Mar 2005 A1
20050049655 Boveja et al. Mar 2005 A1
20050060001 Singhal et al. Mar 2005 A1
20050065562 Rezai Mar 2005 A1
20050065573 Rezai Mar 2005 A1
20050065574 Rezai Mar 2005 A1
20050065575 Dobak Mar 2005 A1
20050070971 Fowler et al. Mar 2005 A1
20050075701 Shafer Apr 2005 A1
20050075702 Shafer Apr 2005 A1
20050101873 Misczynski et al. May 2005 A1
20050107716 Eaton et al. May 2005 A1
20050119703 DiLorenzo Jun 2005 A1
20050124901 Misczynski et al. Jun 2005 A1
20050131467 Boveja et al. Jun 2005 A1
20050131485 Knudson et al. Jun 2005 A1
20050131486 Boveja et al. Jun 2005 A1
20050131493 Boveja et al. Jun 2005 A1
20050143786 Boveja et al. Jun 2005 A1
20050148893 Misczynski et al. Jul 2005 A1
20050148894 Misczynski et al. Jul 2005 A1
20050148895 Misczynski et al. Jul 2005 A1
20050153885 Yun et al. Jul 2005 A1
20050154425 Boveja et al. Jul 2005 A1
20050154426 Boveja et al. Jul 2005 A1
20050165458 Boveja et al. Jul 2005 A1
20050187590 Boveja et al. Aug 2005 A1
20050192644 Boveja et al. Sep 2005 A1
20050197590 Osorio et al. Sep 2005 A1
20050203366 Donoghue et al. Sep 2005 A1
20050245971 Brockway et al. Nov 2005 A1
20050261542 Riehl Nov 2005 A1
20050277998 Tracey et al. Dec 2005 A1
20050283200 Rezai et al. Dec 2005 A1
20050283201 Machado et al. Dec 2005 A1
20050288600 Zhang et al. Dec 2005 A1
20050288760 Machado et al. Dec 2005 A1
20060009815 Boveja Jan 2006 A1
20060018833 Murphy et al. Jan 2006 A1
20060074450 Boveja Apr 2006 A1
20060079936 Boveja Apr 2006 A1
20060094971 Drew May 2006 A1
20060095081 Zhou et al. May 2006 A1
20060106430 Fowler et al. May 2006 A1
20060135877 Giftakis et al. Jun 2006 A1
20060135881 Giftakis et al. Jun 2006 A1
20060149139 Bonmassar et al. Jul 2006 A1
20060155495 Osorio et al. Jul 2006 A1
20060167497 Armstrong et al. Jul 2006 A1
20060173493 Armstrong et al. Aug 2006 A1
20060173522 Osorio Aug 2006 A1
20060190056 Fowler et al. Aug 2006 A1
20060195163 KenKnight et al. Aug 2006 A1
20060200206 Firlik et al. Sep 2006 A1
20060212091 Lozano et al. Sep 2006 A1
20060212097 Varadan et al. Sep 2006 A1
20060224067 Giftakis et al. Oct 2006 A1
20060224191 DiLorenzo Oct 2006 A1
20060241697 Libbus et al. Oct 2006 A1
20060241725 Libbus et al. Oct 2006 A1
20060293720 DiLorenzo Dec 2006 A1
20070027486 Armstrong et al. Feb 2007 A1
20070027497 Parnis et al. Feb 2007 A1
20070027498 Maschino et al. Feb 2007 A1
20070027500 Maschino et al. Feb 2007 A1
20070032834 Gliner et al. Feb 2007 A1
20070043392 Gliner et al. Feb 2007 A1
20070055320 Weinand et al. Mar 2007 A1
20070073150 Gopalsami et al. Mar 2007 A1
20070073355 Dilorenzo Mar 2007 A1
20070088403 Wyler et al. Apr 2007 A1
20070100278 Frei et al. May 2007 A1
20070100392 Maschino et al. May 2007 A1
20070142862 Dilorenzo Jun 2007 A1
20070142873 Esteller et al. Jun 2007 A1
20070150024 Leyde et al. Jun 2007 A1
20070150025 Dilorenzo et al. Jun 2007 A1
20070161919 DiLorenzo Jul 2007 A1
20070162086 DiLorenzo Jul 2007 A1
20070167991 DiLorenzo Jul 2007 A1
20070173901 Reeve Jul 2007 A1
20070173902 Maschino et al. Jul 2007 A1
20070179534 Firlik et al. Aug 2007 A1
20070179557 Maschino et al. Aug 2007 A1
20070179558 Gliner et al. Aug 2007 A1
20070208212 DiLorenzo Sep 2007 A1
20070213785 Osorio et al. Sep 2007 A1
20070233192 Craig Oct 2007 A1
20070239210 Libbus et al. Oct 2007 A1
20070242661 Tran et al. Oct 2007 A1
20070244407 Osorio Oct 2007 A1
20070249953 Osario et al. Oct 2007 A1
20070249954 Virag et al. Oct 2007 A1
20070255147 Drew et al. Nov 2007 A1
20070255155 Drew et al. Nov 2007 A1
20070260147 Giftakis et al. Nov 2007 A1
20070260289 Giftakis et al. Nov 2007 A1
20070265536 Giftakis et al. Nov 2007 A1
20070272260 Nikitin et al. Nov 2007 A1
20070282177 Pilz Dec 2007 A1
20080004904 Tran et al. Jan 2008 A1
20080033503 Fowler et al. Feb 2008 A1
20080033508 Frei et al. Feb 2008 A1
20080046035 Fowler et al. Feb 2008 A1
20080064934 Frei et al. Mar 2008 A1
20080071323 Lowry et al. Mar 2008 A1
20080077028 Schaldach et al. Mar 2008 A1
20080081958 Denison et al. Apr 2008 A1
20080103548 Fowler et al. May 2008 A1
20080114417 Leyde May 2008 A1
20080119900 DiLorenzo May 2008 A1
20080125820 Stahmann et al. May 2008 A1
20080139870 Gliner et al. Jun 2008 A1
20080146890 LeBoeuf et al. Jun 2008 A1
20080146959 Sheffield et al. Jun 2008 A1
20080161712 Leyde Jul 2008 A1
20080161713 Leyde et al. Jul 2008 A1
20080161879 Firlik et al. Jul 2008 A1
20080161880 Firlik et al. Jul 2008 A1
20080161881 Firlik et al. Jul 2008 A1
20080161882 Firlik et al. Jul 2008 A1
20080183096 Snyder et al. Jul 2008 A1
20080183097 Leyde et al. Jul 2008 A1
20080208013 Zhang et al. Aug 2008 A1
20080208284 Rezai et al. Aug 2008 A1
20080258907 Kalpaxis et al. Oct 2008 A1
20080269579 Schiebler et al. Oct 2008 A1
20080275327 Faarbaek et al. Nov 2008 A1
20080275328 Jones et al. Nov 2008 A1
20080275349 Halperin et al. Nov 2008 A1
20080281376 Gerber et al. Nov 2008 A1
20080281381 Gerber et al. Nov 2008 A1
20080281550 Hogle et al. Nov 2008 A1
20080319281 Aarts et al. Dec 2008 A1
20090030345 Bonnet et al. Jan 2009 A1
20090040052 Cameron et al. Feb 2009 A1
20090054737 Magar et al. Feb 2009 A1
20090054742 Kaminska et al. Feb 2009 A1
20090060287 Hyde et al. Mar 2009 A1
20090076350 Bly et al. Mar 2009 A1
20090099624 Kokones et al. Apr 2009 A1
20090099627 Molnar et al. Apr 2009 A1
20090105785 Wei et al. Apr 2009 A1
20090137921 Kramer et al. May 2009 A1
20090227882 Foo Sep 2009 A1
20090227888 Salmi Sep 2009 A1
20090322540 Richardson et al. Dec 2009 A1
20100010382 Panken Jan 2010 A1
20100010392 Skelton et al. Jan 2010 A1
20100010583 Panken et al. Jan 2010 A1
20100023348 Hardee et al. Jan 2010 A1
20100056878 Partin et al. Mar 2010 A1
20100106217 Colborn Apr 2010 A1
20100109875 Ayon et al. May 2010 A1
20100121214 Giftakis et al. May 2010 A1
20100217533 Nadkarni et al. Aug 2010 A1
20100223020 Goetz Sep 2010 A1
20100228103 Schecter Sep 2010 A1
20100228314 Goetz Sep 2010 A1
20100268056 Picard et al. Oct 2010 A1
20100280336 Giftakis et al. Nov 2010 A1
20100280578 Skelton et al. Nov 2010 A1
20100280579 Denison et al. Nov 2010 A1
20100286567 Wolfe et al. Nov 2010 A1
20100298661 McCombie et al. Nov 2010 A1
20100298742 Perlman et al. Nov 2010 A1
20100305665 Miesel et al. Dec 2010 A1
20100312188 Robertson et al. Dec 2010 A1
20110029044 Hyde et al. Feb 2011 A1
20110040204 Ivorra et al. Feb 2011 A1
20110040546 Gerber et al. Feb 2011 A1
20110060252 Simonsen et al. Mar 2011 A1
20110066062 Banet et al. Mar 2011 A1
20110066081 Goto et al. Mar 2011 A1
20110137372 Makous et al. Jun 2011 A1
20110172545 Grudic et al. Jul 2011 A1
20110230730 Quigg et al. Sep 2011 A1
20110245629 Giftakis et al. Oct 2011 A1
20110251469 Varadan Oct 2011 A1
20110270117 Warwick et al. Nov 2011 A1
20110270134 Skelton et al. Nov 2011 A1
20110295127 Sandler et al. Dec 2011 A1
20110306846 Osorio Dec 2011 A1
20110313484 Hincapie et al. Dec 2011 A1
Foreign Referenced Citations (18)
Number Date Country
1145736 Oct 2001 EP
1486232 Dec 2004 EP
2026870 Feb 1980 GB
2079610 Jan 1982 GB
0064336 Nov 2000 WO
2004036377 Apr 2004 WO
2005007120 Jan 2005 WO
2005053788 Jun 2005 WO
2005067599 Jul 2005 WO
2006050144 May 2006 WO
2006122148 Nov 2006 WO
2007066343 Jun 2007 WO
2007072425 Jun 2007 WO
2007124126 Nov 2007 WO
2007124190 Nov 2007 WO
2007124192 Nov 2007 WO
2007142523 Dec 2007 WO
2008045597 Apr 2008 WO
Non-Patent Literature Citations (55)
Entry
Bachman, D.,S. et al.; “Effects Of Vagal Volleys And Serotonin On Units Of Cingulate Cortex in Monkeys;” Brain Research, vol. 130 (1977), pp. 253-269.
Baevsky, R.M. “Analysis of Heart Rate Variability in Space Medicine;” Human Physiology, vol. 28, No. 2, (2002); pp. 202-213.
Baevsky, R.M., et al.; “Autonomic Cardiovascular and Respiratory Control During Prolonged Spaceflights Aboard the International Space Station;”J. Applied Physiological, vol. 103, (2007) pp. 156-161.
Boon, P., et al.; “Vagus Nerve Stimulation for Epilepsy, Clinical Efficacy of Programmed and Magnet Stimulation;” (2001); pp. 93-98.
Boon, Paul, et al.; “Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy;”Journal of Clinical Neurophysiology vol. 18 No. 5; (2001); pp. 402-407.
Borovikova, L.V., et al.; “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin;” Letters to Nature; vol. 405; (May 2000); pp. 458-462.
Brack, Kieran E., et al.; “Interaction Between Direct Sympathetic and Vagus Nerve Stimulation on Heart Rate in the Isolated Rabbit Heart;”Experimental Physiology vol. 89, No. 1; pp. 128-139.
Chakravarthy, N., et al.; “Controlling Synchronization in a Neuron-Level Population Model;” International Journal of Neural Systems, vol. 17, No. 2 (2007) pp. 123-138.
Clark, K.B., et al.; “Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat;” Neurobiology of Learning and Memory, vol. 70, 364-373 (1998).
Elmpt, W.J.C., et al.; “A Model of Heart Rate Changes to Detect Seizures in Severe Epilepsy” Seizure vol. 15, (2006) pp. 366-375.
Frei, M.G., et al.; “Left Vagus Nerve Stimulation with the Neurocybernetic Prosthesis Has Complex Effects on Heart Rate and on Its Variability in Humans:” Epilepsia, vol. 42, No. 8 (2001); pp. 1007-1016.
George, M.S., et al.; “Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy;”Society of Biological Psychiatry vol. 47 (2000) pp. 287-295.
“Heart Rate Variability—Standards of Measurement, Physiological Interpretation, and Clinical Use” Circulation—Electrophysiology vol. 93, No. 5; http://circ.ahajournals.org/cgi/content-nw/full/93/5/1043/F3.
Henry, Thomas R.; “Therapeutic Mechanisms of Vague Name Stimulation;”. Neurology, vol. 59 (Supp 4) (Sep. 2002), pp. S3-S14.
Hallowitz et al., “Effects Of Vagal Volleys On Units Of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys;”Brain Research, vol. 130 (1977), pp. 271-286.
Iasemidis; L.D., et al.; “Dynamical Resetting of the Human Brain at Epilepctic Seizures: Application of Nonlinear Dynamics and Global Optimization Techniques;” IEEE Transactions on Biomedical Engineering, vol. 51, No. 3 (Mar. 2004); pp. 493-506.
Iasemidis; L.D., et al.; “Spatiotemporal Transition to Epileptic Seizures: A Nonlinear Dynamical Analysis of Scalp and Intracranial EEG Recordings;”Spatiotemporal Models in Biological and Artificial Systems; F.L. Silva et al. (Eds.) IOS Press, 1997; pp. 81-88.
Iasemidis, L.D.; “Epileptic Seizure Prediction and Control” IEEE Transactions on Biomedical Engineering, vol. 50, No. 5 (May 2003); pp. 549-558.
Kautzner, J., et al.; “Utility of Short-Term Heart Rate Variability for Prediction of Sudden Cardiac Death After Acute Myocardial Infarction”Acta Univ. Palacki. Olomuc., Fac. Med., vol. 141 (1998) pp. 69-73.
Koenig, S.A., et al.; “Vagus Nerve Stimulation Improves Severely Impaired Heart Rate Variability in a Patient with Lennox-Gastaut-Syndrome” Seizure (2007) Article in Press—Yseiz-1305; pp. 1-4.
Koo, B., “EEG Changes With Vagus Nerve Stimulation” Journal of Clinical Neurophysiology, vol. 18 No. 5 (Sep. 2001); pp. 434-441.
Krittayaphong, M.D., et al.; “Heart Rate Variability in Patients with Coronary Artery Disease: Differences in Patients with Higher and Lower Depression Scores” Psychosomatic Medicine vol. 59 (1997) pp. 231-235.
Leutmezer, F., et al.; “Electrocardiographic Changes at the Onset of Epileptic Seizures;” Epilepsia, vol. 44, No. 3; (2003); pp. 348-354.
Lewis, M.E., et al.; “Vagus Nerve Stimulation Decreases Left Ventricular Contractility in Vivo in the Human and Pig Heart” The Journal of Physiology vol. 534, No. 2, (2001) pp. 547-552.
Li, M., et al.; “Vagal Nerve Stimulation Markedly Improves Long-Term Survival After Chronic Heart Failure in Rats:” Circulation (Jan. 2004) pp. 120-124.
Licht, C.M.M.; Association Between Major Depressive Disorder and Heart Rate Variability in the Netherlands Study of Depression and Anxiety (NESDA); Arch. Gen Psychiatry, vol. 65, No. 12 (Dec. 2008); pp. 1358-1367.
Lockard et al., “Feasibility And Safety Of Vagal Stimulation In Monkey Model;” Epilepsia, vol. 31 (Supp. 2) (1990), pp. S20-S26.
McClintock, P., “Can Noise Actually Boost Brain Power” Physics World Jul. 2002; pp. 20-21.
Mori, T., et al.; “Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves” Physical Review Letters vol. 88, No. 21 (2002); pp. 218101-1-218101-4.
Mormann, F., “Seizure prediction: the long and winding road,” Brain 130 (2007), 314-333.
Nouri, M.D.; “Epilepsy and the Autonomic Nervous System” emedicine (updated May 5, 2006); pp. 1-14; http://www.emedicine.com/neuro/topic658.htm.
O'Regan, M.E., et al.; “Abnormalities in Cardiac and Respiratory Function Observed During Seizures in Childhood” Developmental Medicine & Child Neurlogy, vol. 47 (2005) pp. 4-9.
Pathwardhan, R.V., et al., Control of Refractory status epilepticus precipitated by anticonvulasnt withdrawal using left vagal nerve stimulation: a case report, Surgical Neurology 64 (2005) 170-73.
Poddubnaya, E.P., “Complex Estimation of Adaptation Abilities of the Organism in Children Using the Indices of Responsiveness of the Cardiovascular System and Characteristics of EEG” Neurophysiology vol. 38, No. 1 (2006); pp. 63-74.
Rugg-Gunn, F.J., et al.; “Cardiac Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study” www.thelancet.com vol. 364 (2004) pp. 2212-2219.
Sajadieh, A., et al.; “Increased Heart Rate and Reduced Heart-Rte Variability are Associated with Subclinical Inflammation in Middle-Aged and Elderly Subjects with No Apparent Heart Disease” European Heart Journal vol. 25, (2004); pp. 363-370.
Schernthaner, C., et al.; “Autonomic Epilepsy—The Influence of Epileptic Discharges on Heart Rate and Rhythm”The Middle European Journal of Medicine vol. 111, No. 10 (1999) pp. 392-401.
Terry et al.; “The Implantable Neurocybernetic Prosthesis System”, Pacing and Clinical Electrophysiology, vol. 14, No. 1 (Jan. 1991), pp. 86-93.
Tubbs, R.S., et al.; “Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans” Child's Nervous System Original Paper; Springer-Verlag 2004.
Umetani, M.D., et al.; “Twenty-Four Hour Time Domain Heart Rate Variability and Heart Rate: Relations to Age and Gender Over Nince Decades”JACC vol. 31, No. 3; (Mar. 1998); pp. 593-601.
Vonck, K., et al. “The Mechanism of Action of Vagus Nerve Stimulation for Refractory Epilepsy—The Current Status”, Journal of Neurophysiology, vol. 18 No. 5 (2001), pp. 394-401.
Woodbury, et al., “Vagal Stimulation Reduces the Severity of Maximal Electroshock Seizures in Intact Rats. Use of a Cuff Electrode for Stimulating and Recording”; Pacing and Clinical Electrophysiology, vol. 14 (Jan. 1991), pp. 94-107.
Zabara, J.; “Neuroinhibition of Xylaine Induced Emesis” Pharmacology & Toxicology, vol. 63 (1988) pp. 70-74.
Zabara, J. “Inhibition of Experimental Seizures in Canines by Repetivie Vagal Stimulation” Epilepsia vol. 33, No. 6 (1992); pp. 1005-1012.
Zabara, J., et al.; “Neural Control of Circulation I”The Physiologist, vol. 28 No. 4 (1985); 1 page.
Zabara, J., et al.; “Neuroinhibition in the Regulation of Emesis” Space Life Sciences, vol. 3 (1972) pp. 282-292.
Osorio, Ivan et al., “An Introduction to Contingent (Closed-Loop) Brain Electrical Stimulation For Seizure Blockage, To Ultra-Short-Term Clinical Trials, And To Multidimensional Statistical Analysis Of Therapeutic Efficacy,” Journal Of Clinical Neurophysiology, vol. 18, No. 6, pp. 533-544, 2001.
Osorio, Ivan et al., “Automated Seizure Abatement In Humans Using Electrical Stimulation,” Annals Of Neurology, vol. 57, No. 2, pp. 258-268, 2005.
Sunderam, Sridhar et al., “Vagal And Sciatic Nerve Stimulation Have Complex, Time-Dependent Effects On Chemically-Induced Seizures: A Controlled Study,” Brain Research, vol. 918, pp. 60-66, 2001.
Weil, Sabine et al, “Heart Rate Increase In Otherwise Subclinical Seizures Is Different In Temporal Versus Extratemporal Seizure Onset: Support For Temporal Lobe Automatic Influence,” Epileptic Disord., vol. 7, No. 3, Sep. 2005, pp. 199-204.
Digenarro, Giancarlo et al., “Ictal Heart Rate Increase Precedes EEG Discharge In Drug-Resistant Mesial Temporal Lobe Seizures,” Clinical Neurophysiology, No. 115, 2004, pp. 1169-1177.
Zijlmans, Maeike et al., “Heart Rate Changes And ECG Abnormalities During Epileptic Seizures: Prevalence And Definition Of An Objective Clinical Sign,” Epilepsia, vol. 43, No. 8, 2002, pp. 847-854.
O'Donovan, Cormac A. et al., “Computerized Seizure Detection Based On Heart Rate Changes,” abstract of AES Proceedings, Epilepsia, vol. 36, Suppl. 4, 1995, p. 7.
Robinson, Stephen E et al., “Heart Rate Variability Changes As Predictor Of Response To Vagal Nerve Stimulation Therapy For Epilepsy,” abstract of AES Proceedings,Epilepsia, vol. 40, Suppl. 7, 1999, p. 147.
Long, Teresa J. et al., “Effectiveness Of Heart Rate Seizure Detection Compared To EEG In An Epilepsy MoitoringUnit (EMU),” abstract of AES Proceedings, Epilepsia, vol. 40, Suppl. 7, 1999, p. 174.
Related Publications (1)
Number Date Country
20120029390 A1 Feb 2012 US